- Radiation Therapy
- Targeted Therapy
The MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy was created to support preclinical research and clinical trials in which a patient’s tumor biopsy is assayed for abnormal genes and gene products to select therapy with agents targeting the product of those particular abnormal genes. This integrated research and clinical trials program is aimed at implementing personalized cancer therapy and improving patient outcomes. A number of events have converged creating a “perfect storm” offering the opportunity to make a bold leap forward in personalizing cancer care.
Personalized cancer therapy includes all aspects of individualized patient management driven by characterization of tumor, microenviroment and host characteristics including diagnosis, surgery, chemotherapy, targeted therapy, radiation therapy, and immunological manipulation either alone or in concert.
The Institute is focused on the goal of defining the new standard of patient care – making personalized cancer therapy standard over the next 5 years, revolutionizing the way we manage patients. To accomplish this, we will:
- Rapidly implement the expanded molecular pathology laboratories, technology, instrumentation, and infrastructure for personalized clinical trials.
- Develop best practices for obtaining and managing patient biopsies and specimens to implement personalized cancer therapy.
- Position MD Anderson to lead the way in therapeutic clinical trials based on the underlying genomic and molecular alterations in individual patient’s cancers.
- Establish broad internal and external collaborations and partnerships to enhance our ability to rapidly transform discoveries into clinical practice and standard of care.